The effect of 24 months recombinant human growth hormone (rh-GH) on LDL cholesterol, triglyceride-rich lipoproteins and apo [a] in hypopituitary adults previously treated with conventional replacement therapy

Hypopituitary adults receiving conventional hormone replacement therapy are reported to have increased cardiovascular mortality. Previous studies indicate that these patients have several abnormalities in lipoprotein metabolism, including reduced low density lipoprotein (LDL) uptake and impaired met...

Full description

Saved in:
Bibliographic Details
Published in:Growth hormone & IGF research 1999-06, Vol.9 (3), p.165-173
Main Authors: O’Neal, D.N., Hew, F.L., Best, J.D., Alford, F.
Format: Article
Language:English
Subjects:
Adult
Apolipoproteins A - drug effects
Apolipoproteins A - metabolism
Body Composition - drug effects
Cholesterol, LDL - drug effects
Cholesterol, LDL - metabolism
Female
Growth Hormone - administration & dosage
growth hormone-deficiency, recombinant human growth hormone, liporoteins, low-density lipoprotein, particle size
Hormone Replacement Therapy
Human Growth Hormone - administration & dosage
Humans
Hypopituitarism - drug therapy
Hypopituitarism - metabolism
Insulin - metabolism
Lipoproteins - drug effects
Lipoproteins - metabolism
Male
Middle Aged
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hypopituitary adults receiving conventional hormone replacement therapy are reported to have increased cardiovascular mortality. Previous studies indicate that these patients have several abnormalities in lipoprotein metabolism, including reduced low density lipoprotein (LDL) uptake and impaired metabolism of triglyceride-rich lipoproteins. The effects of 24 months of 0.21 IU/kg per week recombinant growth hormone (rh-GH) on the lipoprotein profiles of 22 GH-deficient adults were studied. Samples were collected after a 12-h fast at baseline and 24 months. Total cholesterol, triglyceride, high-density lipoprotein (HDL) cholesterol, LDL cholesterol, apolipoprotein (apo) A, apo B and apo [a] were determined by routine laboratory methods. LDL particle size was determined by non-denaturing gradient gel electrophoresis. Visceral adiposity was determined by dual energy X-ray absorptiometry (DEXA). Insulin sensitivity was measured in a subset of 17 subjects using a two-stage hyperinsulinaemic-euglycaemic clamp. Significant reductions were observed in total cholesterol (5.3 ± 0.17 vs 4.9 ± 0.23 mmol/l;P
ISSN:1096-6374
1532-2238
DOI:10.1054/ghir.1999.0102